Sònia Servitja

1.9k total citations
54 papers, 1.1k citations indexed

About

Sònia Servitja is a scholar working on Oncology, Genetics and Cancer Research. According to data from OpenAlex, Sònia Servitja has authored 54 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Oncology, 16 papers in Genetics and 16 papers in Cancer Research. Recurrent topics in Sònia Servitja's work include Bone health and treatments (12 papers), Breast Cancer Treatment Studies (12 papers) and Bone health and osteoporosis research (12 papers). Sònia Servitja is often cited by papers focused on Bone health and treatments (12 papers), Breast Cancer Treatment Studies (12 papers) and Bone health and osteoporosis research (12 papers). Sònia Servitja collaborates with scholars based in Spain, United Kingdom and United States. Sònia Servitja's co-authors include Joan Albanell, Ignasi Tusquets, Xavier Nogués, Adolfo Díez‐Pérez, Ana Rovira, Federico Rojo, Daniel Prieto‐Alhambra, Maria Martinez‐García, Sílvia Menéndez and Aňa Lluch and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Sònia Servitja

51 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sònia Servitja Spain	21	734	321	242	224	177	54	1.1k
N.J. Bundred United Kingdom	14	487 0.7×	239 0.7×	199 0.8×	219 1.0×	120 0.7×	39	851
P. Neven Belgium	14	531 0.7×	184 0.6×	222 0.9×	189 0.8×	45 0.3×	24	836
Maria Cincotta Italy	11	529 0.7×	633 2.0×	171 0.7×	207 0.9×	275 1.6×	15	1.3k
Pamela Guglielmini Italy	13	577 0.8×	148 0.5×	468 1.9×	595 2.7×	139 0.8×	24	1.0k
Ning Liu China	20	242 0.3×	428 1.3×	148 0.6×	61 0.3×	82 0.5×	97	1.0k
András Szabó Hungary	14	454 0.6×	1.1k 3.5×	605 2.5×	84 0.4×	204 1.2×	39	1.8k
Tadaaki Taniguchi Japan	18	428 0.6×	738 2.3×	352 1.5×	53 0.2×	84 0.5×	31	1.3k
Marianna Sarkissyan United States	18	429 0.6×	581 1.8×	396 1.6×	106 0.5×	206 1.2×	23	1.1k
Manuel Picon‐Ruiz Spain	14	783 1.1×	687 2.1×	486 2.0×	125 0.6×	90 0.5×	20	1.5k
Yan Liang China	24	229 0.3×	704 2.2×	245 1.0×	72 0.3×	62 0.4×	95	1.4k

Countries citing papers authored by Sònia Servitja

Since Specialization

Citations

This map shows the geographic impact of Sònia Servitja's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sònia Servitja with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sònia Servitja more than expected).

Fields of papers citing papers by Sònia Servitja

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sònia Servitja. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sònia Servitja. The network helps show where Sònia Servitja may publish in the future.

Co-authorship network of co-authors of Sònia Servitja

This figure shows the co-authorship network connecting the top 25 collaborators of Sònia Servitja. A scholar is included among the top collaborators of Sònia Servitja based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sònia Servitja. Sònia Servitja is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Navarro‐Sabaté, Àurea, Rebeca Font, Josep Alfons Espinàs, et al.. (2025). Evaluating the Quality of Real-World Data on Adherence to Oral Endocrine Therapy in Breast Cancer Patients: How Real Is Real-World Data?. Cancers. 17(2). 200–200. 1 indexed citations

Oliveira, Mafalda, Eva Ciruelos, Guillermo Villacampa, et al.. (2025). Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial. Clinical Cancer Research. 32(3). 468–478.

Cortés, Alfonso, Vicente Carañana, Sònia Servitja, et al.. (2024). Olaparib monotherapy in advanced triple-negative breast cancer patients with homologous recombination deficiency and without germline mutations in BRCA1/2: The NOBROLA phase 2 study. The Breast. 78. 103834–103834. 1 indexed citations

Batista, Marta Vaz, José Manuel Pérez-García, Laia Garrigós, et al.. (2024). Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial. ESMO Open. 9(9). 103699–103699. 11 indexed citations

Menéndez, Sílvia, David López, Beatríz Bellosillo, et al.. (2023). Characterization and spatial distribution of the immune cell infiltrate in triple-negative breast cancer: a novel classification based on plasma cells and CD8+ T cells. Human Pathology. 139. 91–105. 5 indexed citations

Batista, Marta Vaz, Antonio Llombart‐Cussac, Manuel Ruíz Borrego, et al.. (2021). 330TiP Trastuzumab deruxtecan (T-DXd; DS-8201) in HER2-positive (HER2+) and HER2-low expressing (HER-LE) metastatic breast cancer (MBC) with brain metastases (BM) and/or leptomeningeal carcinomatosis (LMC): DEBBRAH. Annals of Oncology. 32. S509–S510. 3 indexed citations

González-Santiago, Santiago, Cristina Saura, Eva Ciruelos, et al.. (2020). Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study). Breast Cancer Research and Treatment. 184(2). 469–479. 15 indexed citations

Ayala, Francisco, Raquel Andrés, José Á. García-Sáenz, et al.. (2018). SEOM clinical guidelines in early stage breast cancer (2018). Clinical & Translational Oncology. 21(1). 18–30. 47 indexed citations

Blancas, Isabel, Elena Aguirre, Serafín Morales, et al.. (2018). Real-world data on the efficacy and safety of weekly oral vinorelbine in breast cancer patients previously treated with anthracycline or taxane-based regimens. Clinical & Translational Oncology. 21(4). 459–466. 10 indexed citations

10.

Pineda‐Moncusí, Marta, Miguel Ángel García‐Pérez, Sònia Servitja, et al.. (2018). Vitamin D levels in Mediterranean breast cancer patients compared with those in healthy women. Maturitas. 116. 83–88. 5 indexed citations

11.

Posso, Margarita, Josep Corominas, Laia Serrano, et al.. (2017). Biomarkers expression in benign breast diseases and risk of subsequent breast cancer: a case–control study. Cancer Medicine. 6(6). 1482–1489. 10 indexed citations

12.

Pineda‐Moncusí, Marta, Maica Rodríguez‐Sanz, Adolfo Díez‐Pérez, et al.. (2017). Análisis genético de enzimas de la vía esteroidal asociadas a efectos adversos musculoesqueléticos de los inhibidores de la aromatasa. SHILAP Revista de lepidopterología. 9(2). 72–81. 1 indexed citations

13.

Muntasell, Aura, Mariona Cabo, Sònia Servitja, et al.. (2017). Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy. Frontiers in Immunology. 8. 1544–1544. 65 indexed citations

14.

Rojo, Federico, Abel González-Pérez, Jessica Furriol, et al.. (2016). Non-canonical NF-κB pathway activation predicts outcome in borderline oestrogen receptor positive breast carcinoma. British Journal of Cancer. 115(3). 322–331. 22 indexed citations

15.

Martínez-Jáñez, Noelia, Ana De Juan, Luis de la Cruz‐Merino, et al.. (2016). Anti-HER2 Therapy Beyond Second-Line for HER2- Positive Metastatic Breast Cancer: A Short Review and Recommendations for Several Clinical Scenarios from a Spanish Expert Panel. Breast Care. 11(2). 133–138. 2 indexed citations

16.

Servitja, Sònia, Ana Santaballa, Jacinto Garcı́a, et al.. (2016). CASCADE study: pronounced decline in treatment efficacy through the metastatic life of breast cancer patients. Annals of Oncology. 27. vi76–vi76. 3 indexed citations

17.

García-Parra, Jetzabel, Alba Dalmases, Beatriz Morancho, et al.. (2014). Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer. European Journal of Cancer. 50(15). 2725–2734. 22 indexed citations

18.

Castells, Xavier, Laia Domingo, Josep Corominas, et al.. (2014). Breast cancer risk after diagnosis by screening mammography of nonproliferative or proliferative benign breast disease: a study from a population-based screening program. Breast Cancer Research and Treatment. 149(1). 237–244. 50 indexed citations

19.

Rojo, Federico, Laia Domingo, María Sala, et al.. (2013). Gene Expression Profiling in True Interval Breast Cancer Reveals Overactivation of the mTOR Signaling Pathway. Cancer Epidemiology Biomarkers & Prevention. 23(2). 288–299. 10 indexed citations

20.

Servitja, Sònia, Manuel Ramos, Miguel Gil Gil, et al.. (2011). Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER2. Anti-Cancer Drugs. 23(2). 239–246. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact